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Introduction
The complete sequencing of the human genome in 2001 
revolutionized the molecular era of human disease [1]. 
Of the 3 billion chemical bases comprising the 46 human 
chromosomes,  approximately  30,000  genes  have  been 
mapped. For complex human conditions, such as type 2 
diabetes  mellitus,  coronary  artery  disease  and  endo­
metriosis, the allelic architectures are difficult to charac­
terize  because  they  fail  to  show  classic  Mendelian 
inheritance. Multifactorial or polygenic disorders, such 
as endometriosis, are determined by multiple genes with 
allelic variations. Early studies by the groups of Simpson 
and  Lamb  [2,3]  suggested  that  endometriosis  has  a 
heritable component.
Endometriosis is a common, chronic, inflammatory and 
estrogen­dependent gynecological disease that develops as 
a consequence of a combination of genetic predisposition 
and environmental factors. It affects 10 to 15% of women 
in their reproductive years [4] and is characterized by the 
implantation of endometrial (womb lining) tissue outside 
of the uterus (ectopic endome  trium). Common locations 
of  ectopic  endometrial  im  plan  tation  are  the  pelvic 
peritoneum, ovaries, bowel, bladder, and less frequently, 
the pleural cavity, liver and kidneys.
Endometriosis  is  diagnosed  in  30  to  40%  of  women 
with  infertility  and  pelvic  pain  [5].  Women  frequently 
experience symptoms of dysmenorrhea (painful menstru­
ation),  dyspareunia  (pain  during  sexual  intercourse), 
dysuria (pain during urination) and dyschezia (difficulty 
with defecating). The severity of the disease is graded on 
a scale of I to IV by the revised American Fertility Society 
classification system [6], which quantifies disease accord­
ing to the amount of ectopic endometrial tissue present, 
its  location  and  the  amount  of  scarring  in  the  pelvis. 
Stages  I  and  II  are  described  as  minimal  to  mild  and 
stages III and IV are described as moderate to severe [6]. 
Endometriosis accounts for $22 billion annually in total 
US healthcare costs [7]. Medical treatments are often of 
limited  efficacy,  counterproductive  to  fertility  and  can 
cause  untoward  side  effects  owing  to  suppression  of 
endogenous  steroid  hormone  levels.  Regardless  of 
treatment, endometriotic lesions recur in more than 30% 
of patients with reduced fecundity and pelvic pain [8]. 
Women with endometriosis who have pelvic pain have an 
increased risk of several conditions, including allergies, 
asthma,  autoimmune  diseases,  hypothyroidism  and 
chronic fatigue syndrome [8].
Familial aggregation and twin studies
Beginning in the 1940s, research into the cause of endo­
metriosis included multiple reports of affected relatives, 
suggesting a familial occurrence [9,10]. In a 1971 question­
naire study of 350 women with endometriosis, 22.4% of 
the respondents reported a first­ or second­degree relative 
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first formal genetic studies on women with histologically 
proven  endometriosis  in  1980.  In  this  study,  he  found 
that 6.9% of first­degree relatives also had endometriosis; 
by  contrast,  less  than  1%  of  their  husbands’  female 
relatives had endometriosis [2]. In a follow­up study by 
Malinak et al. [12], the clinical characteristics of patients 
with histologically confirmed pelvic endometriosis who 
had affected relatives were compared with patients who 
had  endometriosis  without  affected  relatives.  The 
primary difference was the finding that women who had 
relatives  with  endometriosis  had  more  severe  disease, 
defined as stages III to IV. The result further supported 
the  role  of  genetics  in  the  pathophysiology  of  endo­
metriosis  and  established  a  7%  risk  of  developing 
endometriosis for first­degree relatives. Lamb et al. [3] 
later estimated an overall risk of 1.9% for second­degree 
relatives.  In  subsequent  familial  aggregation  studies  in 
the UK, Coxhead and Thomas [13] compared 64 women 
with laparoscopically confirmed endometriosis and 128 
controls and found that 9.4% of the patients had first­
degree relatives with endometriosis, yet only 1.6% in the 
control  group  had  relatives  with  endometriosis.  They 
found a sixfold increased risk for first­degree relatives of 
women  with  laparoscopically  confirmed  diagnosis  of 
endometriosis. Moen and Magnus [14] conducted a large 
Norwegian  study  composed  of  522  cases,  which 
supported  the  findings  of  earlier  studies  looking  at 
familial aggregation; 3.9% of mothers and 4.8% of sisters 
of affected individuals had endometriosis compared with 
only 0.6% of sisters in the control group. Interestingly, 
this Norwegian study [14] also concluded that symptom 
severity was increased among women who had relatives 
with endometriosis, a conclusion originally reported in a 
smaller study by Malinak et al. [12].
Icelandic  people,  who  have  been  geographically  and 
genetically isolated, have been an interesting population 
in which to study familial aggregation. A computerized 
database includes all 283,000 presently living Icelanders 
in addition to most of their ancestors since the island was 
settled in the late 9th century. Stefansson et al. [15] used 
this database to study women diagnosed with endo  metri­
osis over a 12­year period (1981 to 1993). They calculated 
the contribution of genetic factors by comparing average 
kinship coefficients. The calculated kinship coefficient in 
750 women with endometriosis was 1.82 × 10­4, which 
was significantly higher (P < 0.001) than that of matched 
controls (1.45 × 10­4).
Twin studies have been used to discern the separate 
contributions of genes and environment. A small Nor­
wegian twin trial reported that six of eight monozygotic 
twin  pairs  were  concordant  for  endometriosis  [16]. 
Hadfield et al. [17] described concordance in 9 out of 16 
monozygotic pairs for stage III to IV endometriosis in a 
larger  British  population  of  twin  pairs.  Of  the  seven 
discordant pairs, there were five pairs in which one twin 
had stage I to II disease and the other had stage III to IV 
disease. Interestingly, the women in the two discordant 
monozygotic twin pairs were all infertile. The observation 
suggests that genes associated with the development of 
endometriosis  may  be  linked  to  genes  that  cause 
infertility.
Linkage analysis studies
Linkage  analysis  has  been  an  important  technique  for 
discovering the chromosomal location of disease­related 
genes. Many monogenetic Mendelian disorders, includ­
ing mutations in the familial breast and ovarian cancer 
genes  BRCA1  and  BRCA2,  have  been  successfully 
mapped using linkage analysis [18,19]. This technique has 
been  used  for  detection  of  genetic  markers  of  endo­
metriosis.  A  large  linkage  study  by  Treloar  et  al.  [20] 
combined  Australian  and  UK  families  and  genotyped 
4,985 women, including 2,709 with endometriosis. The 
collaborative International Endogene Study [20] brought 
together two independent groups: the UK­based Oxford 
Endometriosis  Gene  Study  and  the  Australian  Genes 
behind Endometriosis Study. The study [20] used linkage 
analysis techniques to find two loci of significant linkage 
on chromosome 10q26 and another region of suggestive 
linkage on chromosome 20p13. Chromosome 10q26 had 
previously been implicated in a candidate gene study [21] 
that reported aberrant endometrial EMX2 expression in 
women with endometriosis. EMX2 encodes a trans  crip­
tion factor required for reproductive­tract development 
[22], but variants of EMX2 have not been confirmed to 
contribute  to  the  development  of  endometriosis  [23]. 
Although  promising,  linkage  analysis  has  yielded  few 
significant genetic markers [24].
Genetic association studies
Candidate genes are chosen on the basis of their patho­
physiological relevance and variants of candidate genes 
are  assessed  in  samples  of  endometriosis  cases  and 
controls.  Table  1  summarizes  the  most  commonly 
studied candidate genes. Generally, candidate genes can 
be  divided  into  several  classes:  genes  involved  in 
regulating  xenobiotic  metabolism,  those  involved  in 
steroid  action  and  receptors,  and  those  involved  in 
inflammatory or angiogenic responses (Table 1) [25].
Human  endometrium,  whether  in  its  normal  place 
(eutopic)  or  ectopic,  is  a  hormone­responsive  tissue, 
which  also  produces  steroids,  including  estrogen,  that 
have  been  shown  to  promote  endometriosis  [26].  Risk 
factors of endometriosis include prolonged exposure to 
endogenous estrogen, such as that resulting from early 
menarche or late menopause, and exogenous estrogens. 
Dysregulation  of  progesterone  signaling  in  the  eutopic 
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functions,  including  infertility  and  endometriosis  in 
women [27­29].
Several  association  studies  on  single  nucleotide 
polymorphisms  (SNPs)  of  steroid  receptor  genes  and 
steroid metabolizing genes and endometriosis have been 
performed. Results on the association of estrogen recep­
tor polymorphisms and endometriosis are inconsistent. 
Some studies showed an association of a polymorphism 
(PvuII)  in  the  estrogen  receptor  1  (ESR1)  and  endo­
metriosis [30,31], whereas other studies did not support 
this  association  [32,33].  These  inconsistencies  are 
probably caused by ethnic differences and small sample 
size of association studies. Huber et al. [34] analyzed the 
genotype frequencies of ten estrogen­metabolizing SNPs 
in patients with endometriosis compared with controls. 
Of  these,  the  vIV  A→C  variant  in  the  hydroxysteroid 
(17­β) dehydrogenase 1 (HSD17B1) gene was significantly 
associated  with  an  increased  risk  of  endometriosis  in 
both univariate and multivariate analyses.
Insensitivity  to  progesterone  has  been  suggested  to 
affect both implantation and inflammation in endometri­
osis [26]. The PROGINS polymorphism identified in the 
progesterone receptor (PR) gene contributes to growth 
dysregulation in hormone­sensitive tissues and has been 
associated  with  breast  and  ovarian  cancer  [35].  The 
receptor  change  caused  by  the  PROGINS  mutation  is 
hypothesized  to  affect  ligand­  and  hormone­binding 
properties,  leading  to  inadequate  control  of  estrogen­
receptor­driven proliferation and estrogen overactivation. 
The PROGINS polymorphism is found more frequently 
in  women  diagnosed  with  endometriosis  [36­38],  but 
data  using  genetic  variants  in  the  PR  gene  to  predict 
endo  metriosis are inconclusive in various ethnic popu­
lations [35,39].
Polymorphisms  in  cytokine  genes,  including  tumor 
necrosis factor (TNF)­α, interleukin (IL)-1β, IL-6 and IL-10, 
and  their  receptors  (IL-1RN  and  IL-2Rβ),  have  been 
extensively studied because of the involvement of cytokines 
in the pathogenesis of endometriosis [40]; however, genetic 
variants  of  cytokine  genes  have  not  always  shown  an 
association  with  endometriosis.  For  example,  several 
studies have reported that polymor  phisms in the promoter 
region of the TNF-α gene do not influence endometriosis 
risk in Korean, Taiwanese or Caucasian women [41­43]. 
Similarly, inconsistent find  ings on the association of genetic 
variants and endometriosis have been shown for IL-6 and 
intercellular adhesion molecule 1 (ICAM1) genes [44].
Table 1. Commonly reported endometriosis candidate genes from association studies
        Number  Number 
    Gene  Chromosomal  of positive  of negative 
Process regulated  Candidate gene  symbol  locus  studies  studies
Xenobiotic metabolism  Glutathione M-transferase 1  GSTM1  1p13.3  9  12
  Glutathione S-transferase 1  GSTT1  22q11.2  7  7
  N-acetyl-transferase 2  NAT2  8p22  1  4
  Aryl hydrocarbon receptor repressor  AHRR  5p15  3  1
Hormone receptors or metabolism  Estrogen receptor α   ESR1  6q24-27  8  3
  Progesterone receptor  PR  11q22-33  4  2
  Cytochrome P450, family 17, subfamily A, polypeptide 1  CYP17A1  10q24  3  6
  Cytochrome P450, family 19, subfamily A, polypeptide 1  CYP19A1  15q21  5  2
  Cytochrome P450, family 1, subfamily A, polypeptide 1  CYP1A1  15q24  1  3
  Hydroxysteroid (17-β) dehydrogenase 1  HSD17B1  17q11-21  3  0
Inflammation or angiogenesis  Tumor necrosis factor α  TNFA   6p21.3  2  7
  Interleukin-6  IL-6  7p15.3  4  4
  Interleukin-10  IL-10  1q31-32  7  0
  Vascular endothelial growth factor A  VEGFA  6p21-12  5  1
  Intercellular adhesion molecule 1  ICAM1  19p13  2  3
Other processes  Galactose-1-phosphate uridyl transferase  GALT  9p13  2  2
  Tumor suppressor p53  TP53   17p13  2  7
  HLA class II histocompatibility antigen, DRB1-9 β chain  HLA-DRB1  6p21  3  4
Association studies in English on the most commonly studied candidate genes were identified by performing a PubMed literature search up to 23 June 2010. If a 
published study identified one or more positive associations, we identified this study as positive, otherwise negative. Variants of the ESR2, peroxisome proliferator-
activated receptor γ2 (PPAR-γ2), nuclear factor κB1 (NFKB1), E-cadherin, matrix metalloproteinase 1 (MMP1), MMP9, cyclin dependent kinase inhibitor p27 (CDKN1B), 
neurokinin-1 (TAC1),nitric oxide synthase 3 (NOS3), fibroblast growth factor 1 (FGF1), FGF2 and catechol-O-methyltransferase (COMT) genes have also been 
investigated as candidate genes potentially associated with endometriosis.
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dioxin, have been implicated in the pathogenesis of endo­
metriosis in rhesus macaques [45] and in women [46,47]. 
Glutathione S­transferases (GSTs) are enzymes involved 
in the detoxification of a broad range of toxic compounds 
and carcinogens, including dioxin [48]. Two of the most 
studied SNPs in detoxification enzymes are in the GST 
genes GSTM1 and GSTT1, which are located on chromo­
some 1p13.3 and 22q11.2, respectively. A meta­analysis 
by Guo [49] involving 14 studies on GSTM1 and 9 studies 
on GSTT1 concluded that there was no increased risk for 
women  with  the  GSTM1  null  genotype  and  a  slightly 
increased risk for those with a GSTT1 polymorphism.
Table 1 summarizes the variable results of the endo­
metri  osis  and  gene  polymorphism  association  studies. 
These  discrepancies  may  be  due  to  methodological 
problems, including relatively small numbers of cases and 
controls  and  selection  of  control  populations  [44]. 
Another explanation may be the use of different geno­
typing techniques. In addition, there is difficulty control­
ling  environmental  factors  and  problems  replicating 
results among different ethnic populations. Large, multi­
center prospective cohort studies with DNA genotyping 
arrays and gene­gene and gene­environment studies of 
endometriosis are needed.
Genome-wide association studies
High­resolution  genomic  tools  enabling  genome­wide 
association studies (GWASs) [50] offer the prospect of 
making  real  progress  in  the  discovery  of  genes  contri­
buting to risk of multi­factorial diseases such as endo­
metriosis. GWASs have been performed successfully in 
the discovery of new genomic regions that are associated 
with  multifactorial  diseases  [51,52].  The  methodology 
examines  variation  across  the  genome  using  compu­
tational models to compare the genotypes of people with 
and  without  disease  to  identify  SNPs  associated  with 
disease. Sufficient power using this approach necessitates 
thousands  of  subjects,  but  this  can  be  achieved  by 
collaboration  of  large  consortia.  The  advantage  of  this 
method is that hundreds of thousands of SNPs can be 
quickly examined for potential associations [53]. Another 
advantage of GWASs is that they are unbiased and do not 
depend  on  biologically  plausible  candidate  genes  or 
specific polymorphisms [54]. Disadvantages are that very 
large sample sizes are necessary to derive meaningful and 
reproducible  conclusions  valuable  for  characterizing 
poly  genic diseases such as endometriosis.
Several large population­based prospective cohorts in 
the  United  States,  Europe,  Australia  and  Japan  have 
gathered  endometriosis  data  and  represent  potential 
sources for GWASs. These include the American Cali­
fornia Teacher Study [55], the Nurses’ Health Study II 
[56,57], the National Health and Nutrition Examination 
Survey  [58],  the  French  E3N  Cohort  study  [59],  the 
Australian Genes behind Endometriosis Study [60], the 
Oxford  Endometriosis  Gene  Study  [61],  the  Icelandic 
Endometriosis Cohort Study [15] and the BioBank Japan 
project  [62].  From  these  different  cohorts,  extensive 
time­dependent covariate data have been collected [56]. 
The  cohorts  differ  in  prevalence  of  current  infertility, 
surgical diagnosis, age distribution, selection of controls 
and ethnicity. The first large endometriosis GWAS was 
published  by  Uno  et  al.  [63]  using  the  endometriosis 
cohort from the Biobank Japan project (1,907 Japanese 
endometriosis cases and 5,292 controls). They identified 
an association of endometriosis with the SNP rs10965235 
located in the cyclin­dependent kinase inhibitor 2B anti­
sense  RNA  (CDKN2BAS)  gene  on  chromosome  9p21 
(with an odds ratio of 1.44) and with rs16826658m in the 
linkage disequilibrium block that includes the signaling 
gene WNT4 on chromosome 1p36 [63]. WNT4 signaling 
has a role in the coordination of female ovarian follicle 
development  and  of  the  development  of  the  fallopian 
tubes and uterus from the Müllerian (paramesonephric) 
ducts  [64].  CDKN2BAS  regulates  the  expression  of 
CDKN2A,  a  cell­cycle  kinase  inhibitor  that  controls 
endometrial proliferation and has been attributed with a 
role in endometriosis [65].
Interestingly, this GWAS [63] has confirmed loci such 
as  9p21  that  are  shared  with  conditions  previously 
thought  to  be  unrelated  to  endometriosis,  including 
coro  nary  artery  disease.  Recent  studies  have  revealed 
that genetic variants in 9p21 are associated with multi­
factorial diseases, including coronary artery disease, type 
2  diabetes,  malignant  melanoma,  basal  cell  carcinoma, 
nevi (moles) and glioma [66­69]. The clinical relevance of 
identified  genetic  variants  for  predicting  risk  of  endo­
metriosis is unclear because the overall increase in risk 
caused  by  the  known  variants  is  small  [70].  However, 
GWASs represent a new frontier in the investigation of 
gene­gene and gene­environment interactions. Predictive 
power  may  improve  as  more  susceptibility  loci  are 
identified and new computational tools are applied.
Conclusions
We  have  seen  progress  in  the  understanding  of 
endometriosis in the past decade through linkage analysis 
and  association  studies.  However,  the  pathophysiology 
and genetics of endometriosis are still unclear. The long­
term  goals  in  discovering  the  genetic  basis  of  endo­
metriosis are early detection and improved treatment of 
endometriosis­associated symptoms, including infertility 
and  pelvic  pain.  GWASs  may  bring  insight  into  gene­
environment  interaction  and  identify  candidate  genes 
that are associated with endometriosis. This promising 
new  technology  has  the  potential  for  finding  modest 
associations for polygenic diseases such as endometriosis. 
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from  the  predominantly  case­control  study  design  and 
the  difficulty  of  interpreting  statistics  that  result  from 
multiple  hypothesis  testing.  They  need  to  be  further 
validated  through  replication  studies  that  find  similar 
associations  among  independent  samples  with  large, 
appropriately powered populations. The credibility and 
validity  of  GWASs  will  be  further  increased  when 
consistent statistical results are combined with evidence 
of  biological  functionality  for  the  variants  found. 
Thereafter,  data  from  GWASs  could  be  used  to  assess 
individual risk for endometriosis and may be useful in 
counseling women for early treatment in order to avoid 
sequelae  such  as  infertility.  In  addition,  GWAS  dis­
coveries  could  be  implemented  in  the  development  of 
novel  therapies  for  the  treatment  of  endometriosis. 
Genetics­based  diagnostic  tests  for  endometriosis  and 
genetically  targeted  therapies  hold  the  promise  to 
diagnose and treat women at a younger age and allow 
physicians to better advise women regarding prognosis.
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